Combination Therapy with Anti-MUC1 Monoclonal Antibody and Docetaxel Reduces Tumor Burden in Ovarian Cancer Model
Author Information
Author(s): Wang Li, Chen Hongmin, Pourgholami Mohammad H., Beretov Julia, Hao Jingli, Chao Hongtu, Perkins Alan C., Kearsley John H., Li Yong
Primary Institution: Department of Gynecologic Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China; Faculty of Medicine, University of New South Wales, Sydney, Australia
Hypothesis
Can the combination of anti-MUC1 monoclonal antibody C595 and docetaxel effectively reduce tumor burden and improve survival in an ovarian cancer model?
Conclusion
The combination of anti-MUC1 monoclonal antibody C595 and docetaxel significantly reduces tumor burden and ascites, and prolongs survival in a mouse model of ovarian cancer.
Supporting Evidence
- The combination treatment significantly reduced ascites volume and tumor weight compared to controls.
- Survival rates were higher in the combination treatment group than in the control groups.
- Histological analysis showed reduced MUC1 expression in tumors treated with the combination therapy.
Takeaway
Researchers found that using a special antibody along with a chemotherapy drug helped mice with ovarian cancer live longer and have smaller tumors.
Methodology
Mice with ovarian cancer were treated with either the antibody, docetaxel, or a combination of both, and their tumor growth, ascites volume, and survival were measured.
Limitations
The study was conducted in a mouse model, which may not fully replicate human ovarian cancer.
Participant Demographics
Female athymic nude mice, 6-8 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website